Mersana Therapeutics (MRSN) Tops Q1 EPS by 2c

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $9.24 million versus the consensus estimate of $7.93 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Acuity Brands (AYI) Tops Q3 EPS by 15c
• Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim